Health & Fitness
Wed, March 14, 2012Tue, March 13, 2012Mon, March 12, 2012Sat, March 10, 2012Fri, March 9, 2012Thu, March 8, 2012Wed, March 7, 2012Tue, March 6, 2012Mon, March 5, 2012Fri, March 2, 2012Thu, March 1, 2012Celsion Corporation to Hold Year-End 2011 Financial Results Conference Call on Thursday, March 15, 2012
Published in Health and Fitness on Thursday, March 8th 2012 at 5:08 GMT by Market Wire
March 08, 2012 08:00 ET
Celsion Corporation to Hold Year-End 2011 Financial Results Conference Call on Thursday, March 15, 2012
LAWRENCEVILLE, NJ--(Marketwire - Mar 8, 2012) - Celsion Corporation (
The call will be archived for replay on Thursday, March 15, 2012 at 2:00 p.m. ET and will remain available until Thursday, March 29, 2012. The replay can be accessed at 1-877-870-5176 (Toll-Free/North America) or 1-858-384-5517 (International/Toll) using Conference ID: 3234714. An audio replay of the call will also be available on the Company's website, [ http://www.celsion.com ], for 30 days after 2:00 p.m. ET on Thursday, March 15, 2012.
About Celsion Corporation
Celsion is a leading oncology company dedicated to the development and commercialization of innovative cancer drugs including tumor-targeting treatments using focused heat energy in combination with its heat-activated liposomal drug technology. Celsion has research, license, or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, the University of Pisa, the UCLA Department of Medicine, Kyungpook National University Hospital and the Beijing Cancer Hospital.
For more information on Celsion, visit our website: [ http://www.celsion.com ].
Celsion wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbour" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
